{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:38:42Z","timestamp":1761885522232,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.acuroe.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:48:25Z","timestamp":1677268105000},"page":"329-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?"],"prefix":"10.1016","volume":"47","author":[{"given":"F.","family":"Guerrero-Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2023.01.009_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0020","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0025","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00345-010-0626-3","article-title":"Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study","volume":"29","author":"Porter","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0040","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2010.05.037","article-title":"Lessons learned from 1,000 neobladders: the 90-day complication rate","volume":"184","author":"Hautmann","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0045","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0050","first-page":"93","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"Alvarez-Maestro","year":"2021","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0055","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations From the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0060","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0065","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2023.01.009_bib0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623000185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578623000185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:16:32Z","timestamp":1761880592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578623000185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2173578623000185"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.01.009","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2023.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}